Loading...
Loading...
Credit Suisse raises its rating on Medtronic
MDT from Neutral to Outperform and increases its price from $43 to $44.
Credit Suisse notes, "We now see an improving top-line for MDT as achievable expect execution in emerging markets combined with recovery in key developed markets (consistent with F4Q's US ICD results) & tuck-in acquisitions to drive valuation expansion over the next 12 months. Given improving growth prospects, MDT's attractive FCF profile ($4.4B expected in FY13, ~12% implied FCF yield) and valuation (currently trades at 9x our FY14 EPS estimate vs. 5 year NTM average of 12x & trough of 8x), we now feel comfortable upgrading to Outperform from Neutral."
MDT closed at $36.82 on Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in